eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
6/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Basic research

Down-regulation of miR-203a by lncRNA PVT1 in multiple myeloma promotes cell proliferation

Man Yang, Lingxiu Zhang, Xiufeng Wang, Yanjun Zhou, Sun Wu

Arch Med Sci 2018; 14, 6: 1333–1339
Online publish date: 2018/03/08
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Emerging evidence has indicated that long non-coding RNAs (lncRNAs) play vital roles in multiple myeloma (MM) development and progression. However, the underlying mechanism of PVT1 in MM remains unclear.

Material and methods
QRT-PCR was used to detect the expression of PVT1 and miR-203a in MM samples and cell lines. The effects of PVT1 on MM cell proliferation and apoptosis were determined by CCK8 assay and flow cytometer assay, respectively. Bioinformatics methods were used to identify the downstream target miRNAs of PVT1.

Results
We found that the expression of PVT1 was upregulated in MM samples and cell lines (p < 0.05), while the expression of miR-203a was downregulated in MM samples and cell lines (p < 0.05). There was a negative correlation between PVT1 expression and miR-203a expression in MM samples (p < 0.05). In in vitro function assays, we found that PVT1 inhibition suppressed MM cell proliferation and induced MM cell apoptosis (p < 0.05). The bioinformatics approach predicted that PVT1 sponge miR-203a would modulate MM cells. Rescue experiments confirmed the recovering roles of miR-203a for PVT1 on MM progression.

Conclusions
In the present study, we found that lncRNA PVT1 could promote MM cell proliferation and induce cell apoptosis by inhibiting miR-203a expression. Therefore, PVT1 may represent a potential therapeutic target for the treatment of MM patients.

keywords:

multiple myeloma, miR-203a, PVT1, proliferation, apoptosis

references:
Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-20.
Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011; 183: 25-35.
Fu J. Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance. Arch Med Sci 2017; 13: 236-45.
Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-6.
Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-33.
Esquela-Kerscher A, Slack FJ. Oncomirs – microRNAs with a role in cancer. Nature Rev Cancer 2006; 6: 259-69.
Hua J, Ding T, Yang L. Dysfunction of microRNA-32 regulates ubiquitin ligase FBXW7 in multiple myeloma disease. Oncot Targets Ther 2016; 9: 6573-9.
Wu S, He X, Li M, et al. MiRNA-34a overexpression inhibits multiple myeloma cancer stem cell growth in mice by suppressing TGIF2. Am J Transl Res 2016; 8: 5433-43.
Qin Y, Zhang S, Deng S, et al. Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia 2017; 31: 1123-35.
Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nature Rev Genet 2009; 10: 155-9.
Shen X, Zhang Y, Wu X, et al. Upregulated lncRNA-PCAT1 is closely related to clinical diagnosis of multiple myeloma as a predictive biomarker in serum. Cancer Biomark 2017; 18: 257-63.
Cho SF, Chang YC, Chang CS, et al. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer 2014; 14: 809.
Alvarez ML, DiStefano JK. Functional characterization of the plasmacytoma variant translocation 1 gene (PVT1) in diabetic nephropathy. PLoS One 2011; 6: e18671.
Huang C, Yu W, Wang Q, et al. Increased expression of the lncRNA PVT1 is associated with poor prognosis in pancreatic cancer patients. Minerva Med 2015; 106: 143-9.
Song J, Wu X, Liu F, et al. Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. Biochem Biophys Res Commun 2017; 490: 217-24.
Zhang D, Sun G, Zhang H, Wang X, Tian J, Li Y. Long non-coding RNA PVT1 facilitates cervical cancer progression through negative modulation of miR-128-3p. Int J Clin Exp Pathol 2017; 10: 4522-9.
Wan C, Shen Y, Yang T, et al. Diagnostic value of micro­RNA for pancreatic cancer: a meta-analysis. Arch Med Sci 2012; 8: 749-55.
Chen W, Zhu H, Yin L, et al. lncRNA-PVT1 facilitates invasion through upregulation of MMP9 in nonsmall cell lung cancer cell. DNA Cell Biol 2017; 36: 787-93.
Zhou Q, Chen J, Feng J, Wang J. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor (TSHR). Tumor Biol 2016; 37: 3105-13.
Zhang D, Sun G, Zhang H, Wang X, Tian J, Li Y. Long non-coding RNA PVT1 facilitates cervical cancer progression through negative modulation of miR-128-3p. Int J Clin Exp Pathol 2017; 10: 4522-9.
Ebert MS, Sharp PA. MicroRNA sponges: progress and possibilities. RNA 2010; 16: 2043-50.
Wang Z, Yuan J, Li L, Yang Y, Xu X, Wang Y. Long non-coding RNA XIST exerts oncogenic functions in human glioma by targeting miR-137. Am J Transl Res 2017; 9: 1845-55.
Zhu J, Shi H, Liu H, Wang X, Li F. Long non-coding RNA TUG1 promotes cervical cancer progression by regulating the miR-138-5p-SIRT1 axis. Oncotarget 2017; ;8: 65253-64.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe